Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectively As of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...

Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra ...

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization to Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic ...

Bill Sibold, Chief Executive Officer of Madrigal, stated, “The introduction of Rezdiffra as the first and only FDA-approved therapy in NASH marks a turning point for Madrigal and the NASH community.

Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra ...

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectivelyAs of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, ...

Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark Office issued a Notice of Allowance for a new U.S. patent related to the ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...